



Steroid-Responsive Idiopathic Pulmonary Hemosiderosis in Adulthood: A Case Report.

Krishnan Namboothiri E¹, Deependra Kumar Rai², Somesh Thakur³, Javeeria Shabbir¹, Jisha G. Panicker¹, Sheetal Verma¹, Thaodem Collin^{1*}

¹Senior Resident, Department of Pulmonary Medicine, AIIMS, Patna, Bihar, India

²Professor, Department of Pulmonary Medicine, AIIMS Patna, Bihar, India

³Additional Professor, Department of Pulmonary Medicine, AIIMS Patna, Bihar, India

Page | 1

Abstract

Background:

Idiopathic pulmonary hemosiderosis (IPH) is a rare cause of diffuse alveolar hemorrhage (DAH), most commonly reported in children but occasionally seen in adults.

Case Presentation:

We describe a 30-year-old woman with recurrent hemoptysis, anemia, and dyspnea for two years. Investigations revealed iron deficiency anemia, diffuse ground-glass opacities on HRCT, and hemosiderin-laden macrophages on bronchoalveolar lavage. Transbronchial biopsy confirmed pulmonary hemosiderosis. She was treated with oral corticosteroids (0.75 mg/kg/day), resulting in complete clinical and radiological resolution within one month.

Conclusion:

This case highlights the importance of considering IPH in adults presenting with unexplained DAH and anemia, particularly in tuberculosis-endemic regions. Early recognition and corticosteroid therapy can lead to favorable outcomes.

Keywords: Idiopathic pulmonary hemosiderosis, diffuse alveolar hemorrhage, hemoptysis, corticosteroids, case report

Submitted: April 19, 2026 **Accepted:** May 20, 2026 **Published:** June 01, 2026

Corresponding Author: Thaodem Collin

Email: thaodemcollin@gmail.com

Senior Resident, Department of Pulmonary Medicine, AIIMS Patna, Bihar, India.

Introduction

Idiopathic pulmonary hemosiderosis (IPH) is an uncommon and poorly understood cause of diffuse alveolar hemorrhage (DAH). Although predominantly described in children, adult presentations have been documented. The incidence is extremely low, estimated at 0.2–1.2 per million. The classical clinical triad includes recurrent hemoptysis, anemia, and dyspnea, but the disease often presents with variable severity. Because IPH lacks a specific diagnostic marker, it is considered a diagnosis of exclusion after other causes of DAH have been ruled out.

The rarity of IPH frequently leads to delayed recognition, which can cause significant distress for patients and families. Pathogenesis remains unclear, and evidence for optimal treatment is limited, with few randomized clinical trials available. Hemoptysis is the most common symptom, occurring either intermittently or persistently, and the

amount of bleeding varies considerably. Clinicians should maintain a high index of suspicion and include IPH in the differential diagnosis of DAH and chronic anemia, even in atypical cases (Butt et al., 2020). The wide spectrum of clinical manifestations—from mild recurrent bleeding to severe respiratory failure—underscores the need for a comprehensive diagnostic approach and individualized therapeutic strategies (Saha & Milman, 2022).

Case Report

A 30-year-old woman presented with a 2-year history of chest pain, recurrent hemoptysis, and exertional breathlessness. She denied fever, abdominal pain, skin rash, joint pain, mucosal ulcers, ocular redness, hematuria, or anorexia. There was no history of prior medications, comorbidities, or addictions. Family history was negative for pulmonary, hematological, or autoimmune disease, and



no significant psychosocial or occupational/environmental exposures were reported.

Examination

Pallor was noted, with no clubbing, cyanosis, icterus, or lymphadenopathy. Vital signs: pulse 86/min, blood pressure 110/70 mmHg, respiratory rate 20/min. Chest auscultation revealed normal vesicular breath sounds bilaterally; systemic examination was otherwise unremarkable.

Investigations

- **Blood tests:** Iron deficiency anemia (serum iron 35 µg/dl, saturation 5%). Peripheral smear showed microcytic hypochromic RBCs with macrocytes, teardrop cells, pencil cells, and target cells. WBC count 6700/µL, platelet count $2.67 \times 10^5/\mu\text{L}$, reticulocyte count 4.62%.
- **Other labs:** Coagulation profile, liver and renal function tests, and urine microscopy were normal. Autoimmune markers (ANA, RF, anti-dsDNA, ANCA, anti-GBM, antiphospholipid antibodies) were negative. Sputum CBNAAT was negative.
- **Bone marrow biopsy:** Cellular marrow with trilineage hematopoiesis.
- **Pulmonary function:** Spirometry showed moderate restriction with increased DLCO.
- **Imaging:** Chest X-ray revealed bilateral patchy ground-glass opacities and increased bronchovascular marking in mid and lower zones (Fig.1). HRCT thorax showed bilateral extensive ground-glass opacities with right lower lobe bronchiectasis (Fig.2).
- **Bronchoscopy:** BAL demonstrated hemosiderin-laden macrophages. Transbronchial lung biopsy report consistent with pulmonary hemosiderosis (Fig.3).

- **Other:** Upper GI endoscopy showed fissuring of the D2 fold; biopsy was normal.

Differential Diagnosis

At presentation, the differential diagnosis included pulmonary tuberculosis, Goodpasture syndrome, ANCA-associated vasculitis, and other systemic causes of diffuse alveolar hemorrhage. These were considered given the clinical picture of hemoptysis with anemia in a tuberculosis-endemic region, and were subsequently excluded on the basis of negative sputum CBNAAT, negative autoimmune serology, and the absence of other systemic features.

Management

Oral glucocorticoids (0.75 mg/kg/day) were initiated. Within one month, the patient became asymptomatic, and chest imaging showed complete resolution (Fig.4). The specific corticosteroid agent used, total treatment duration, tapering schedule, and whether therapy was continued beyond this one-month resolution point were not specified in the available records [authors to add these details].

Follow-up

Follow-up beyond the one-month assessment was not documented in the original case data [authors to add duration of subsequent follow-up, whether relapse occurred, and status at last contact].

Adverse Events

No corticosteroid-related adverse effects or unanticipated clinical events during the diagnostic workup were reported in the original case data [authors to confirm whether any adverse events occurred, or state explicitly that none were noted].



Figure 1: Chest X-ray, PA view, bilateral patchy ground-glass opacities and increased bronchovascular markings




Figure 2: HRCT thorax showed bilateral extensive ground-glass opacities with right lower lobe bronchiectasis




Figure 3: Trans bronchial lung biopsy showing alveolar tissue; septa are thickened due to fibrosis and infiltration of hemosiderin-laden macrophages



Figure 4: Chest X-ray PA view after 1 month of treatment showed complete resolution

Discussion

IPH is a rare disorder, with most cases occurring in children under 10 years. Adult presentations, such as in this patient, are unusual. Hemoptysis with anemia is a common

presentation, but in tuberculosis-endemic regions, IPH is often misdiagnosed as pulmonary tuberculosis, delaying recognition and treatment.



The pathogenesis remains unclear. Proposed mechanisms include oxidative stress, immune-mediated capillary injury, and endothelial damage, all contributing to recurrent hemorrhage, hemosiderin deposition, inflammation, and fibrosis (Saha & Milman, 2022). Structural defects in pulmonary capillary endothelium or basement membrane have also been suggested.

Clinical manifestations vary widely. Some patients remain asymptomatic, while others develop recurrent dyspnea, cough, hemoptysis, or even respiratory failure. Chronic disease may present with pallor, growth retardation, or features of fibrosis such as bilateral crackles and clubbing. In this case, recurrent hemoptysis and exertional dyspnea were the predominant symptoms.

Diagnosis requires exclusion of other causes of DAH, including infections, Goodpasture syndrome, ANCA-associated vasculitis, and systemic diseases. Investigations such as chest imaging, spirometry, bronchoscopy, and lung biopsy are essential. BAL has a higher diagnostic yield than sputum analysis, while histology showing hemosiderin-laden macrophages remains the gold standard.

Corticosteroids are the cornerstone of therapy. Immunosuppressants (e.g., azathioprine, mycophenolate mofetil) may be considered in steroid-resistant cases. Our patient responded well to corticosteroids, with complete clinical and radiological resolution.

Conclusion

Idiopathic pulmonary hemosiderosis is a rare but important cause of DAH and chronic anemia. Adult presentations are uncommon and often misdiagnosed. Early recognition and prompt corticosteroid therapy can lead to favorable outcomes. This case emphasizes the need for heightened clinical suspicion in patients with unexplained recurrent hemoptysis and anemia.

Informed Consent

Written informed consent was obtained from the patient for publication of this case report.

List of Abbreviations

IPH	Idiopathic Pulmonary Hemosiderosis
DAH	Diffuse Alveolar Hemorrhage
HRCT	High-Resolution Computed Tomography
BAL	Bronchoalveolar Lavage

DLCO	Diffusing Capacity of the Lung for Carbon Monoxide
ANA	Antinuclear Antibody
RF	Rheumatoid Factor
ANCA	Anti-Neutrophil Cytoplasmic Antibody
Anti-GBM	Anti-Glomerular Basement Membrane Antibody
CBNAAT	Cartridge-Based Nucleic Acid Amplification Test
RBC	Red Blood Cell
GI	Gastrointestinal

Source of Funding

No funding or financial support was received for this study.

Conflict of Interest

The authors declare that there are no conflicts of interest regarding the publication of this case report.

Author Contributions

Krishnan Namboothiri E: Participated in patient management, data collection, literature review, and manuscript preparation.

Deependra Kumar Rai: Contributed to clinical supervision, interpretation of findings, and critical revision of the manuscript.

Somesh Thakur: Assisted in diagnostic evaluation, data interpretation, and manuscript editing.

Javeeria Shabbir: Contributed to literature review and manuscript drafting.

Jisha G. Panicker: Participated in patient follow-up, data acquisition, and manuscript review.

Sheetal Verma: Assisted in literature review and revision of the manuscript for important intellectual content.

Thaodem Collin: Conceived the study, supervised the work, critically reviewed the manuscript, and approved the final version for publication.

All authors read and approved the final manuscript.

Author Biographies

Dr. Krishnan Namboothiri E

MD, Department of Pulmonary Medicine, All India Institute of Medical Sciences (AIIMS), Patna, Bihar, India. His areas of interest include diffuse parenchymal lung diseases, bronchoscopy, and pulmonary infections.



Student's Journal of Health Research Africa

e-ISSN: 2709-9997, p-ISSN: 3006-1059

Vol.7 No. 2 (2026): June 2026 Issue

<https://doi.org/10.51168/sjhrafrica.v7i2.2693>

Case Report

Page | 5

Dr. Deependra Kumar Rai

Professor, Department of Pulmonary Medicine, AIIMS Patna, Bihar, India. His research interests include interstitial lung diseases, pulmonary infections, and critical care pulmonology.

Dr. Somesh Thakur

Associate Professor, Department of Pulmonary Medicine, AIIMS Patna, Bihar, India. His areas of interest include bronchoscopy, interventional pulmonology, and respiratory critical care.

Dr. Javeeria Shabbir

Senior Resident, Department of Pulmonary Medicine, AIIMS Patna, Bihar, India. Her interests include pulmonary medicine, bronchoscopy, and rare respiratory disorders.

Dr. Jisha G. Panicker

Senior Resident, Department of Pulmonary Medicine, AIIMS Patna, Bihar, India. Her research interests include diffuse alveolar hemorrhage syndromes and interstitial lung diseases.

Dr. Sheetal Verma

Assistant Professor, Department of Pulmonary Medicine, AIIMS Patna, Bihar, India. Her interests include respiratory infections, interstitial lung disease, and clinical research.

Dr. Thaodem Collin

Professor and Head, Department of Pulmonary Medicine, AIIMS Patna, Bihar, India. His academic interests include pulmonary medicine, interventional pulmonology, and rare lung diseases.

References

1. Butt A, Ahmed R, Sheikh MDA, Khan O, Iqbal N, Rahman AJ, Khan JA. Idiopathic pulmonary hemosiderosis - A rare cause of chronic anemia. Monaldi Arch Chest Dis. 2020;90(2). <https://doi.org/10.4081/monaldi.2020.1267>
2. Saha BK, Milman N. Liposteroid therapy for idiopathic pulmonary hemosiderosis: A scoping review of the literature. Prague Med Rep. 2022;123(2):65. <https://doi.org/10.14712/23362936.2022.6>

PUBLISHER DETAILS:

Student's Journal of Health Research (SJHR)

(ISSN 2709-9997) Online

(ISSN 3006-1059) Print

Category: Non-Governmental & Non-profit Organization

Email: studentsjournal2020@gmail.com

WhatsApp: +256 775 434 261

**Location: Scholar's Summit Nakigalala, P. O. Box 701432,
Entebbe Uganda, East Africa**

